886366-33-2

Usage

Appearance

White crystalline powder

Molecular weight

241.10 g/mol

Usage

a. Organic synthesis
b. Pharmaceutical research
c. Building block for synthesis of biologically active compounds
d. Reagent in production of specialty chemicals

Chemical reactivity

a. Versatile compound in organic chemistry
b. Ability to undergo various types of chemical reactions

Upstream product

• 124276-83-1 1-(3-bromophenyl)cyclopropane-1-carbonitrile 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 1878-67-7 3-Bromophenylacetic acid 
• 749928-59-4 methyl 1-(3-bromophenyl)cyclopropane-1-carboxylate 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 

Downstream Products

• 1346690-16-1 3-(1-{[(triisopropylsilyl)oxy]methyl}cyclopropyl)benzaldehyde 
• 1346690-17-2 [3-(1-{[(triisopropylsilyl)oxy]methyl}cyclopropyl)phenyl]methanol 
• 1418296-16-8 (1-{3-[(3-{(Z)-1-fluoro-2-[4-(trifluoromethoxy)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]-phenyl}cyclopropyl)methanol 
• 1418296-19-1 (1-{3-[(3-{(Z)-1-fluoro-2-[3-fluoro-4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]vinyl}-5-methyl-1H-pyrazol-1-yl)methyl]phenyl}cyclopropyl)methanol 
• 1346690-15-0 {[1-(3-bromophenyl)cyclopropyl]methoxy}(triisopropyl)silane 

Relevant academic research and scientific papers

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

MACROCYCLIC FACTOR VIIA INHIBITORS

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.

SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS

The present application relates to novel substituted 5-(1,2,4-oxadiazol-5-yl)pyridin-2-ones and 6-(1,2,4-oxadiazol-5-yl)pyridazin-3-ones, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for producing medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.

3-(Fluorovinyl)pyrazoles and their use

The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.